SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 6-K
REPORT OF FOREIGN ISSUER
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
Date of Report: June 8, 2000
BIORA AB
SE-205 12 Malmo, Sweden
Telephone: (011) 46-40-32-13-33
Indicate by a check mark whether the registrant files or will
file annual reports under cover of Form 20-F or Form 40-F.
|X| Form 20-F |_| Form 40-F
Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.
|_| Yes |X| No
If "Yes" is marked, indicate below the file number assigned to
the registrant in connection with Rule 12g3-2(b):
Not applicable.
This Form 6-K consists of a press release issued by Biora AB on
June 8, 2000 regarding the hiring of a new executive at their German
division.
No 7/00, June 8, 2000 FOR IMMEDIATE RELEASE
Home page:www.biora.com
BIORA APPOINTS NEW GENERAL MANAGER IN GERMANY
Malmo, June 8, Biora AB (NASDAQ:BIORY, SSE BIOR) announced that Mr.
Wolfgang Muller has joined Biora GmbH, Biora's German subsidiary as General
Manager of both the Germany and Austrian markets.
"We are delighted to welcome Wolfgang Muller back to Biora and we look
forward to a rewarding collaboration with him. The most important goal for
Wolfgang is to improve a good sales potential and growth in the German
market," says Tomas Hammargren, President and CEO of Biora.
Wolfgang Muller, previously the Sales Manager at Biora GmbH, has rejoined
Biora and is delighted in his new role to have the opportunity to develop
and contribute to the company's success.
"With such a unique product as Emdogain(R) and the enthusiasm that
exists in the company, it is certainly stimulating to return," says
Wolfgang Muller.
Biora develops manufactures and sells products for the treatment of
periodontal disease and for use in oral surgery. Using its proprietary
technology and expertise, Biora aims to become a world leader in
biology-based products for specialized dental therapy. Biora's American
Depository Shares are listed on the Nasdaq National Market in the US and
Biora's ordinary shares are listed on the "O-list" of the Stockholm Stock
Exchange in Sweden.
This press release may contain certain forward-looking statements that
relate to future events or future business and financial performance. Such
statements can only be predictions and the actual events or results may
differ from those discussed. The Company cautions that these statements are
subject to important factors that could cause actual results to differ
materially from those expressed or implied in such forward looking
statements and are more fully discussed in periodic reports filed with
Securities and Exchange Commission.
President and CEO Investor Relations U.S Investor Relations
Tomas Hammargren Mikael Sjoblom Elisabeth Lavers
+46 40 32 13 36 + 46 40 32 13 65 +1 203 977 7797
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
BIORA AB
Dated: June 8, 2000 By: /s/ Anders Agering
----------------------------------
Anders Agering
Chief Financial Officer
